Submitted by Administrator on Mon, 07/12/2020 - 17:54
Trial results, published in the Journal of Clinical Oncology by Professor Tim Eisen (Department of Oncology and CRUK Cambridge Centre Urological Malignancies Programme), have concluded that active observation remains the best care for kidney cancer patients after surgery. Over 1,700 patients participated in the double-blind, randomised trial assessing the efficacy of sorafenib (a tyrosine kinase inhibitor also known as Nexavar) for prolonging life and preventing recurrence of kidney cancer in patients who are at medium or high risk of their cancer returning.
More information